Follow
Kelly Holloway
Kelly Holloway
Assistant Professor (status), University of Toronto
Verified email at utoronto.ca
Title
Cited by
Cited by
Year
Too few, too weak: conflict of interest policies at Canadian medical schools
A Shnier, J Lexchin, B Mintzes, A Jutel, K Holloway
PloS one 8 (7), e68633, 2013
572013
Conflict of interest as ethical shorthand: understanding the range and nature of “non-financial conflict of interest” in biomedicine
Q Grundy, C Mayes, K Holloway, S Mazzarello, BD Thombs, L Bero
Journal of clinical epidemiology 120, 1-7, 2020
462020
Normalizing complaint: Scientists and the challenge of commercialization
KJ Holloway
Science, Technology, & Human Values 40 (5), 744-765, 2015
392015
Blood donation and the global COVID‐19 pandemic: areas for social science research
J Haw, K Holloway, BM Masser, EM Merz, R Thorpe
Vox sanguinis 116 (4), 363, 2021
382021
Half a century of Wilson & Jungner: reflections on the governance of population screening
S Sturdy, F Miller, S Hogarth, N Armstrong, P Chakraborty, C Cressman, ...
Wellcome Open Research 5, 2020
292020
A responsibility to commercialize? Tracing academic researchers’ evolving engagement with the commercialization of biomedical research
KHM Herder
Journal of Responsible Innovation, 2019
242019
‘Something there is that doesn’t love a wall’: Histories of the placental barrier
A Martin, K Holloway
Studies in History and Philosophy of Science Part C: Studies in History and …, 2014
222014
Uneasy subjects: Medical students' conflicts over the pharmaceutical industry
K Holloway
Social Science & Medicine 114, 113-120, 2014
222014
Health Canada needs to act on laboratory-developed diagnostics
K Holloway, FA Miller, F Rousseau, A Gutierrez, S Hogarth
CMAJ 191 (39), E1067-E1069, 2019
172019
Industry, experts and the role of the ‘invisible college’in the dissemination of non-invasive prenatal testing in the US
K Holloway, FA Miller, N Simms
Social science & medicine 270, 113635, 2021
142021
Dangerous diagnostics? Regulatory reform in the genomic era
K Holloway, FA Miller, A Gutierrez, S Hogarth
BMJ 364, 2019
92019
Understanding the experiences of plasma donors in Canada's new source plasma collection centres during COVID‐19: A qualitative study
K Holloway
Vox Sanguinis, 2022
82022
The market in noninvasive prenatal tests and the message to consumers: exploring responsibility
K Holloway, N Simms, RZ Hayeems, FA Miller
Hastings Center Report 52 (2), 49-57, 2022
82022
Blood collection agency messaging to donors and the public in Canada and Australia during the early days of COVID-19
J Haw, R Thorpe, K Holloway
Frontiers in Communication 6, 777829, 2022
82022
The Consultant's intermediary role in the regulation of molecular diagnostics in the US
K Holloway, FA Miller
Social science & medicine 304, 112929, 2022
62022
Teaching conflict: Professionalism and medical education
KJ Holloway
Journal of bioethical inquiry 12, 675-685, 2015
62015
What influences decisions to donate plasma? A rapid review of the literature
M Berger, A Easterbrook, K Holloway, D Devine, N Bansback
Vox Sanguinis 118 (10), 817-824, 2023
32023
How do we forecast tomorrow’s transfusion? Applying social science approaches to meet tomorrow’s transfusion needs: Blood donors and donation
J Haw, K Holloway, M Goldman
Transfusion Clinique et Biologique 30 (1), 47-51, 2023
22023
‘A Most Equitable Drug’: How the Clinical Studies of Convalescent Plasma as a Treatment for SARS-CoV-2 Might Usefully Inform Post-Pandemic Public Sector Approaches to Drug …
Q Grundy, C Campbell, R Ali, M Herder, K Holloway
The Journal of Law, Medicine & Ethics, 2023
22023
“A Most Equitable Drug”: How the Clinical Studies of Convalescent Plasma as a Treatment for SARS-CoV-2 Might Usefully Inform Post-Pandemic Public Sector Approaches to Drug …
Q Grundy, C Campbell, R Ali, M Herder, K Holloway
Journal of Law, Medicine & Ethics 52 (1), 80-97, 2024
12024
The system can't perform the operation now. Try again later.
Articles 1–20